Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia

Lina Reslan

Open source

DOI
10.70675/275b41b7ze51dz4061zb119z87e18302dbad
Published
Not recorded
Container
Not recorded
Publisher
Agence Bibliographique de l'Enseignement Supérieur
Open access
unknown

Credibility signals

uncertain Score 58/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.70675/275b41b7ze51dz4061zb119z87e18302dbad,
  title = {Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia},
  author = {Lina Reslan},
  doi = {10.70675/275b41b7ze51dz4061zb119z87e18302dbad},
  url = {https://doi.org/10.70675/275b41b7ze51dz4061zb119z87e18302dbad}
}

RIS

TY  - JOUR
TI  - Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia
AU  - Lina Reslan
DO  - 10.70675/275b41b7ze51dz4061zb119z87e18302dbad
UR  - https://doi.org/10.70675/275b41b7ze51dz4061zb119z87e18302dbad
ER  - 

APA

Reslan, L. (n.d.). Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia. https://doi.org/10.70675/275b41b7ze51dz4061zb119z87e18302dbad

Source records